Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Interesting editorial comment from Tomasz Beer, MD, re: the ADXS-PSA press release:

A badly misleading title. This study could not determine if survival is prolonged by the combination. The only thing that this trial can demonstrate is that the combination tested is tolerable and feasible. It will be interesting to see it move beyond phase I. But for now, we know it is feasible.



So at least you know people are paying attention, but we have to be careful about getting ahead of ourselves in terms of data interpretation.